2462 related articles for article (PubMed ID: 23873146)
41. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis.
Griesinger G; Diedrich K; Devroey P; Kolibianakis EM
Hum Reprod Update; 2006; 12(2):159-68. PubMed ID: 16254001
[TBL] [Abstract][Full Text] [Related]
42. Withdrawal of GnRH agonist decreases oestradiol and VEGF concentrations in high responders.
Ding LJ; Wang B; Shen XY; Yan GJ; Zhang NY; Hu YL; Sun HX
Reprod Biomed Online; 2013 Aug; 27(2):131-9. PubMed ID: 23764202
[TBL] [Abstract][Full Text] [Related]
43. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
[TBL] [Abstract][Full Text] [Related]
44. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
[TBL] [Abstract][Full Text] [Related]
45. Reproductive Outcome After GnRH Agonist Triggering With Co-Administration of 1500 IU hCG on the Day of Oocyte Retrieval in High Responders: A Long-Term Retrospective Cohort Study.
Abdulkhalikova D; Bokal EV; Stimpfel M; Ciglar P; Korosec S
Front Endocrinol (Lausanne); 2022; 13():826411. PubMed ID: 35464066
[TBL] [Abstract][Full Text] [Related]
46. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
Orvieto R
J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
[TBL] [Abstract][Full Text] [Related]
47. Gonadotropin-releasing hormone agonist for ovulation trigger - OHSS prevention and use of modified luteal phase support for fresh embryo transfer.
Castillo JC; Haahr T; Martínez-Moya M; Humaidan P
Ups J Med Sci; 2020 May; 125(2):131-137. PubMed ID: 32366146
[TBL] [Abstract][Full Text] [Related]
48. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.
Manzanares MA; Gómez-Palomares JL; Ricciarelli E; Hernández ER
Fertil Steril; 2010 Mar; 93(4):1215-9. PubMed ID: 19200978
[TBL] [Abstract][Full Text] [Related]
49. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol.
Orvieto R; Nahum R; Zohav E; Liberty G; Anteby EY; Meltcer S
Gynecol Endocrinol; 2013 Jan; 29(1):51-3. PubMed ID: 22857268
[TBL] [Abstract][Full Text] [Related]
50. Rescue hCG to treat empty follicle syndrome after the use of a GnRH agonist as oocyte maturation trigger: First report on fresh embryo transfer and clinical pregnancy.
Christopoulos G; Vlismas A; Barsoum-Derias E; El-Shawarby S; Trew G; Lavery S
Hum Fertil (Camb); 2015; 18(4):248-52. PubMed ID: 26400626
[TBL] [Abstract][Full Text] [Related]
51. Repeated GnRH agonist doses for luteal support: a proof of concept.
Wiser A; Klement AH; Shavit T; Berkovitz A; Koren RR; Gonen O; Amichay K; Shulman A
Reprod Biomed Online; 2019 Nov; 39(5):770-776. PubMed ID: 31628035
[TBL] [Abstract][Full Text] [Related]
52. Ultrasound and hematological changes during early luteal phase in women at high risk for developing ovarian hyperstimulation syndrome.
Lainas GT; Lainas TG; Venetis CA; Sfontouris IA; Zorzovilis IZ; Alexopoulou E; Tarlatzis BC; Kolibianakis EM
Ultrasound Obstet Gynecol; 2018 Jan; 51(1):126-133. PubMed ID: 29105961
[TBL] [Abstract][Full Text] [Related]
53. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support.
Castillo JC; Dolz M; Bienvenido E; Abad L; Casañ EM; Bonilla-Musoles F
Reprod Biomed Online; 2010 Feb; 20(2):175-81. PubMed ID: 20113955
[TBL] [Abstract][Full Text] [Related]
54. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols.
Toftager M; Bogstad J; Løssl K; Prætorius L; Zedeler A; Bryndorf T; Nilas L; Pinborg A
Hum Reprod; 2017 Mar; 32(3):556-567. PubMed ID: 28130435
[TBL] [Abstract][Full Text] [Related]
55. Severe ovarian hyperstimulation syndrome after combined GnRH-agonist and low-dose human chorionic gonadotropin trigger in a patient with a single kidney.
Pereira N; Lekovich JP; Kligman I; Rosenwaks Z
Gynecol Endocrinol; 2017 Aug; 33(8):593-597. PubMed ID: 28440686
[TBL] [Abstract][Full Text] [Related]
56. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
[TBL] [Abstract][Full Text] [Related]
57. A drop in serum progesterone from oocyte pick-up +3 days to +5 days in fresh blastocyst transfer, using hCG-trigger and standard luteal support, is associated with lower ongoing pregnancy rates.
Uyanik E; Mumusoglu S; Polat M; Yarali Ozbek I; Esteves SC; Humaidan P; Yarali H
Hum Reprod; 2023 Feb; 38(2):225-236. PubMed ID: 36478179
[TBL] [Abstract][Full Text] [Related]
58. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
[TBL] [Abstract][Full Text] [Related]
59. Incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders after gonadotropin-releasing hormone (GnRH) agonist trigger in "freeze-all" approach.
Fernández-Sánchez M; Fatemi H; García-Velasco JA; Heiser PW; Daftary GS; Mannaerts B
Gynecol Endocrinol; 2023 Dec; 39(1):2205952. PubMed ID: 37156263
[TBL] [Abstract][Full Text] [Related]
60. Luteal phase support with GnRH agonist does not eliminate the risk for ovarian hyperstimulation syndrome.
Friedler S; Grin L
Gynecol Endocrinol; 2019 May; 35(5):368-369. PubMed ID: 30614333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]